Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms

Breast Cancer Research

Volumn 12, Issue 2, 2010, Pages

  Rowe, Bryan P ^a   Glazer, Peter M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 IODO 3 NITROBENZAMIDE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; AG 14361; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CEP 9722; DNA TOPOISOMERASE INHIBITOR; GEMCITABINE; INO 1001; MK 4827; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VELIPARIB; 2 ((R) 2 METHYLPYRROLIDIN 2 YL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE; BENZIMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; DRUG DOSE ESCALATION; DRUG MECHANISM; EXCISION REPAIR; FANCONI ANEMIA; HOMOLOGOUS RECOMBINATION; HUMAN; HYPOXIA; MELANOMA; MISMATCH REPAIR; OVARY CANCER; REVIEW; SOLID TUMOR; BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; METABOLISM;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DNA DAMAGE; DNA REPAIR; FEMALE; HUMANS; INDOLES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 77956631770     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2566     Document Type: Review

References (85)

1. Hall E, Giaccia A. Repair of radiation damage and the dose-rate effect. Radiobiology for the Radiologist 2006, 67-90. Philadelphia: Lippincott Williams & Wilkins, McAllister L, 6.
2. Chan KK, Zhang QM, Dianov GL. Base excision repair fidelity in normal and cancer cells. Mutagenesis 2006, 21:173-178. 10.1093/mutage/gel020, 16613912.
3. Robertson AB, Klungland A, Rognes T, Leiros I. DNA repair in mammalian cells: base excision repair: the long and short of it. Cell Mol Life Sci 2009, 66:981-993. 10.1007/s00018-009-8736-z, 19153658.
4. Hanawalt PC. Subpathways of nucleotide excision repair and their regulation. Oncogene 2002, 21:8949-8956. 10.1038/sj.onc.1206096, 12483511.
5. Kinsella TJ. Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin Cancer Res 2009, 15:1853-1859. 10.1158/1078-0432.CCR-08-1307, 19240165.
6. Pardo B, Gomez-Gonzalez B, Aguilera A. DNA repair in mammalian cells: DNA double-strand break repair: how to fix a broken relationship. Cell Mol Life Sci 2009, 66:1039-1056. 10.1007/s00018-009-8740-3, 19153654.
7. Moldovan GL, D'Andrea AD. How the Fanconi anemia pathway guards the genome. Annu Rev Genet 2009, 43:223-249. 2830711, 19686080, 10.1146/annurev-genet-102108-134222.
8. Roschke AV, Glebov OK, Lababidi S, Gehlhaus KS, Weinstein JN, Kirsch IR. Chromosomal instability is associated with higher expression of genes implicated in epithelial-mesenchymal transition, cancer invasiveness, and metastasis and with lower expression of genes involved in cell cycle checkpoints, DNA repair, and chromatin maintenance. Neoplasia 2008, 10:1222-1230. 2570598, 18953431.
9. Chen S, Parmigiani G. Meta-Analysis of BRCA1 and BRCA2 Penetrance. J Clin Oncol 2007, 25:1329-1333. 2267287, 17416853, 10.1200/JCO.2006.09.1066.
10. Jasin M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene 2002, 21:8981-8993. 10.1038/sj.onc.1206176, 12483514.
11. Chen JJ, Silver D, Cantor S, Livingston DM, Scully R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res 1999, 59(7 Suppl):1752s-1756s.
12. Yang H, Li Q, Fan J, Holloman WK, Pavletich NP. The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA-ssDNA junction. Nature 2005, 433:653-657. 10.1038/nature03234, 15703751.
13. Boulton SJ. Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans 2006, 34:633-645. 10.1042/BST0340633, 17052168.
14. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell 1999, 4:511-518. 10.1016/S1097-2765(00)80202-6, 10549283.
15. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000, 408:429-432. 10.1038/35044000, 11100717.
16. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004, 432:316-323. 10.1038/nature03097, 15549093.
17. Ganesan S, Silver DP, Greenberg RA, Avni D, Drapkin R, Miron A, Mok SC, Randrianarison V, Brodie S, Salstrom J, Rasmussen TP, Klimke A, Marrese C, Marahrens Y, Deng CX, Feunteun J, Livingston DM. BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell 2002, 111:393-405. 10.1016/S0092-8674(02)01052-8, 12419249.
18. Bhattacharyya A, Ear U, Koller B, Weichselbaum R, Bishop D. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000, 275:23899-23903. 10.1074/jbc.C000276200, 10843985.
19. Tutt A, Lord C, McCabe N, Farmer H, Turner N, Martin N, Jackson S, Smith G, Ashworth A. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005, 70:139-148. 10.1101/sqb.2005.70.012, 16869747.
20. Liu N, Lamerdin J, Tebbs R, Schild D, Tucker J, Shen M, Brookman K, Siciliano M, Walter C, Fan W, Narayana L, Zhou Z, Adamson A, Sorensen K, Chen D, Jones N, Thompson L. XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA crosslinks and other damages. Mol Cell 1998, 1:783-793. 10.1016/S1097-2765(00)80078-7, 9660962.
21. Akkari YM, Bateman RL, Reifsteck CA, Olson SB, Grompe M. DNA replication is required To elicit cellular responses to psoralen-induced DNA interstrand cross-links. Mol Cell Biol 2000, 20:8283-8289. 86436, 11027296, 10.1128/MCB.20.21.8283-8289.2000.
22. Cass I, Baldwin R, Varkey T, Moslehl R, Narod S, Karlan B. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003, 97:2187-2195. 10.1002/cncr.11310, 12712470.
23. Treszezamsky A, Kachnic L, Feng Z, Zhang J, Tokadjian C, Powell S. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res 2007, 67:7078-7081. 10.1158/0008-5472.CAN-07-0601, 17671173.
24. Taniguchi T, Garcia-Higuera I, Xu B, Andreassen PR, Gregory RC, Kim ST, Lane WS, Kastan MB, D'Andrea AD. Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways. Cell 2002, 109:459-472. 10.1016/S0092-8674(02)00747-X, 12086603.
25. Andreassen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev 2004, 18:1958-1963. 514175, 15314022, 10.1101/gad.1196104.
26. Pichierri P, Averbeck D, Rosselli F. DNA cross-link-dependent RAD50/MRE11/NBS1 subnuclear assembly requires the Fanconi anemia C protein. Hum Mol Genet 2002, 11:2531-2546. 10.1093/hmg/11.21.2531, 12354779.
27. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M, D'Andrea AD. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001, 7:249-262. 10.1016/S1097-2765(01)00173-3, 11239454.
28. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D'Andrea AD. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003, 9:568-574. 10.1038/nm852, 12692539.
29. Ferrer M, de Winter JP, Mastenbroek DC, Curiel DT, Gerritsen WR, Giaccone G, Kruyt FA. Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA. Cancer Gene Ther 2004, 11:539-546. 10.1038/sj.cgt.7700734, 15192709.
30. Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, Kennedy R, Foster R, Mahoney J, Seiden MV, D'Andrea AD. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 2006, 5:952-961. 10.1158/1535-7163.MCT-05-0493, 16648566.
31. Benachenhou N, Guiral S, Gorska-Flipot I, Labuda D, Sinnett D. Frequent loss of heterozygosity at the DNA mismatch-repair loci hMLH1 and hMSH3 in sporadic breast cancer. Br J Cancer 1999, 79:1012-1017. 2362257, 10098729, 10.1038/sj.bjc.6690162.
32. Naqvi RA, Hussain A, Deo SS, Kukreti H, Chauhan M, Sarin R, Saxena A, Asim M, Shukla NK, Husain SA, Pasha ST, Basir SF. Hypermethylation analysis of mismatch repair genes (hmlh1 and hmsh2) in locally advanced breast cancers in Indian women. Hum Pathol 2008, 39:672-680. 10.1016/j.humpath.2007.09.011, 18329696.
33. Karray-Chouayekh S, Trifa F, Khabir A, Boujelbane N, Sellami-Boudawara T, Daoud J, Frikha M, Gargouri A, Mokdad-Gargouri R. Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma. J Biomed Biotechnol 2009, 2009:369129. 2717605, 19644562.
34. Murata H, Khattar NH, Gu L, Li GM. Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer. Cancer Lett 2005, 223:143-150. 10.1016/j.canlet.2004.09.039, 15890247.
35. Zeng M, Narayanan L, Xu XS, Prolla TA, Liskay RM, Glazer PM. Ionizing radiation-induced apoptosis via separate Pms2- and p53-dependent pathways. Cancer Res 2000, 60:4889-4893.
36. Fritzell JA, Narayanan L, Baker SM, Bronner CE, Andrew SE, Prolla TA, Bradley A, Jirik FR, Liskay RM, Glazer PM. Role of DNA mismatch repair in the cytotoxicity of ionizing radiation. Cancer Res 1997, 57:5143-5147.
37. Jagtap P, Szabó C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005, 4:421-440. 10.1038/nrd1718, 15864271.
38. Huber A, Bai P, de Murcia JM, de Murcia G. PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development. DNA Repair 2004, 3:1103-1108. 10.1016/j.dnarep.2004.06.002, 15279798.
39. de Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, Oliver FJ, Masson M, Dierich A, LeMeur M, Walztinger C, Chambon P, de Murcia G. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 1997, 94:7303-7307. 23816, 9207086, 10.1073/pnas.94.14.7303.
40. Schreiber V, Amé JC, Dollé P, Schultz I, Rinaldi B, Fraulob V, Ménissier-de Murcia J, de Murcia G. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 2002, 277:23028-23036. 10.1074/jbc.M202390200, 11948190.
41. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007, 13:1383-1388. 10.1158/1078-0432.CCR-06-2260, 17332279.
42. Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T, Santarosa M, Dillon K, Hickson I, Knights C, Martin N, Jackson S, Smith G, Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921. 10.1038/nature03445, 15829967.
43. Bryant H, Schultz N, Thomas H, Parker K, Flower D, Lopez E, Kyle S, Meuth M, Curtin N, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917. 10.1038/nature03443, 15829966.
44. Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005, 5:689-698. 10.1038/nrc1691, 16110319.
45. Iglehart JD, Silver DP. Synthetic lethality- a new direction in cancer-drug development. N Engl J Med 2009, 361:189-191. 10.1056/NEJMe0903044, 19553640.
46. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4:814-819. 10.1038/nrc1457, 15510162.
47. Kirkegaard T, Nielsen KV, Jensen LB, Campbell FM, Müller S, Tovey SM, Brown S, Cooke TG, Bartlett JM. Genetic alterations of CCND1 and EMSY in breast cancers. Histopathology 2008, 52:698-705. 10.1111/j.1365-2559.2008.03007.x, 18393977.
48. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006, 66:8109-8115. 10.1158/0008-5472.CAN-06-0140, 16912188.
49. Willers H, Taghian AG, Luo CM, Treszezamsky A, Sgroi DC, Powell SN. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol Cancer Res 2009, 7:1304-1309. 19671671, 10.1158/1541-7786.MCR-09-0149.
50. Powell SN, Bindra RS. Targeting the DNA damage response for cancer therapy. DNA Repair (Amst) 2009, 8:1153-1165. 10.1016/j.dnarep.2009.04.011, 19501553.
51. Choudhury A, Cuddihy A, Bristow R. Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol 2006, 16:51-58. 10.1016/j.semradonc.2005.08.007, 16378907.
52. Fong P, Boss D, Yap T, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor M, Ashworth A, Carmichael J, Kaye S, Schellens J, de Bono J. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134. 10.1056/NEJMoa0900212, 19553641.
53. Kopetz S, Mita M, Mok I, Sankhala K, Moseley J, Sherman B, Bradley C, Tolcher A. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors [abstract]. J Clin Oncol 2008, 26(15S):3577.
54. Curtin N, Wang L, Yiakouvaki A, Kyle S, Arris C, Canan-Koch S, Webber S, Durkacz B, Calvert H, Hostomsky Z, Newell D. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 2004, 10:881-889. 10.1158/1078-0432.CCR-1144-3, 14871963.
55. Cheng C, Johnson S, Keir S, Quinn J, Ali-Osman F, Szabo C, Li H, Salzman A, Dolan M, Modrich P, Bigner D, Friedman H. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005, 4:1364-1368. 10.1158/1535-7163.MCT-05-0128, 16170028.
56. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJ. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004, 96:56-67.
57. Liu X, Shi Y, Guan R, Donawho C, Luo Y, Palma J, Zhu G, Johnson EF, Rodriguez LE, Ghoreishi-Haack N, Jarvis K, Hradil VP, Colon-Lopez M, Cox BF, Klinghofer V, Penning T, Rosenberg SH, Frost D, Giranda VL, Luo Y. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Mol Cancer Res 2008, 6:1621-1629.
58. Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, Ator M, Bihovsky R, Hudkins R, Chatterjee S, Klein-Szanto A, Dionne C, Ruggeri B. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003, 2:371-382.
59. Stachelek GC, Dalal S, Donigan KA, Campisi Hegan D, Sweasy JB, Glazer PM. Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation. Cancer Res 2010, 70:409-417. 10.1158/0008-5472.CAN-09-1353, 20028873.
60. Bowman KJ, Newell DR, Calvert AH, Curtin NJ. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 2001, 84:106-112. 2363607, 11139322, 10.1054/bjoc.2000.1555.
61. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, Durkacz BW, Hostomsky Z, Newell DR. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000, 6:2860-2867.
62. Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, Wang H, Sandler A, Johnson DH, Colevas AD, Low J, Rothenberg ML, Lu B. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007, 13:3033-3042. 10.1158/1078-0432.CCR-06-2872, 17505006.
63. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007, 13:2728-2737. 10.1158/1078-0432.CCR-06-3039, 17473206.
64. Brock WA, Milas L, Bergh S, Lo R, Szabó C, Mason KA. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett 2004, 205:155-160. 10.1016/j.canlet.2003.10.029, 15036647.
65. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert H. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008, 14:7917-7923. 2652879, 19047122, 10.1158/1078-0432.CCR-08-1223.
66. Plummer R, Lorigan P, Evans J, Steven N, Middleton M, Wilson R, Snow K, Dewji R, Calvert H. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM) [abstract]. J Clin Oncol 2006, 24(18S):8013.
67. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz P, Vernillet L, Hwu P. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest 2009, 27:756-763. 10.1080/07357900802709159, 19440934.
68. Yan L, Bulgar A, Miao Y, Mahajan V, Donze JR, Gerson SL, Liu L. Combined treatment with temozolomide and methoxyamine: blocking apurinic/pyrimidinic site repair coupled with targeting topoisomerase IIa. Clin Cancer Res 2007, 13:1532-1539. 10.1158/1078-0432.CCR-06-1595, 17332299.
69. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 2003, 29:297-307. 10.1016/S0305-7372(03)00003-3, 12927570.
70. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007, 25:4066-4074. 10.1200/JCO.2007.12.7878, 17827455.
71. Ewing D. The oxygen fixation hypothesis: a reevaluation. Am J Clin Oncol 1998, 21:355-361. 10.1097/00000421-199808000-00008, 9708633.
72. Bindra RS, Crosby ME, Glazer PM. Regulation of DNA repair in hypoxic cells. Cancer Metastasis Rev 2007, 26:249-260. 10.1007/s10555-007-9061-3, 17415527.
73. Liu SK, Coackley C, Krause M, Jalali F, Chan N, Bristow RG. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol 2008, 88:258-268. 10.1016/j.radonc.2008.04.005, 18456354.
74. Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer PM. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci 2010, 107:2201-2206. 10.1073/pnas.0904783107, 20133863.
75. Mihaylova VT, Bindra RS, Yuan J, Campisi D, Narayanan L, Jensen R, Giordano F, Johnson RS, Rockwell S, Glazer PM. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol Cell Biol 2003, 23:3265-3273. 153206, 12697826, 10.1128/MCB.23.9.3265-3273.2003.
76. Shahrzad S, Quayle L, Stone C, Plumb C, Shirasawa S, Rak JW, Coomber BL. Ischemia-induced K-ras mutations in human colorectal cancer cells: role of microenvironmental regulation of MSH2 expression. Cancer Res 2005, 65:8134-8141. 10.1158/0008-5472.CAN-05-0713, 16166287.
77. Koshiji M, To KK, Hammer S, Kumamoto K, Harris AL, Modrich P, Huang LE. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell 2005, 17:793-803. 10.1016/j.molcel.2005.02.015, 15780936.
78. Bindra RS, Schaffer PJ, Meng A, Woo J, Måseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, Glazer PM. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 2004, 24:8504-8518. 516750, 15367671, 10.1128/MCB.24.19.8504-8518.2004.
79. Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, Bristow RG, Classon MK, Glazer PM. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 2005, 65:11597-11604. 10.1158/0008-5472.CAN-05-2119, 16357170.
80. Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, Belmaaza A, Wouters B, Bristow RG. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008, 68:605-614. 10.1158/0008-5472.CAN-07-5472, 18199558.
81. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 2009, 69:1221-1229. 10.1158/0008-5472.CAN-08-2516, 19141645.
82. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451:1116-1120. 2577037, 18264087, 10.1038/nature06633.
83. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451:1111-1116. 10.1038/nature06548, 18264088.
84. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008, 68:2581-2586. 2674369, 18413725, 10.1158/0008-5472.CAN-08-0088.
85. Miknyoczki SJ, Chang H, Grobelny J, Pritchard S, Worrell C, McGann N, Ator M, Hursten J, Deibold J, Hudkins R, Zulli A, Parchment R, Ruggeri B. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther 2007, 6:2290-2302. 10.1158/1535-7163.MCT-07-0062, 17699724.